PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Gesamtlänge aller Episoden: 8 days 18 minutes
Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice
Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice
Ask, Spot, Refer: Identifying Acute Hepatic Porphyria in the Emergency Room
Ask, Spot, Refer: Identifying Acute Hepatic Porphyria in the Emergency Room
Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC
Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC
Managing Cytopenic Myelofibrosis: New and Emerging Therapies and Who May Benefit
Managing Cytopenic Myelofibrosis: New and Emerging Therapies and Who May Benefit
Metabolic Health of PLWH: What Needs to Be Considered When Initiating or Switching ART?
Metabolic Health of PLWH: What Needs to Be Considered When Initiating or Switching ART?
Personalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions
Personalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions
Reassessing Management of Advanced and Recurrent Endometrial Cancer: The Value of Multidisciplinary and Overall Care
Reassessing Management of Advanced and Recurrent Endometrial Cancer: The Value of Multidisciplinary and Overall Care
Question Time: Applying New Therapies for the Management of mTNBC
Question Time: Applying New Therapies for the Management of mTNBC
Managing Generalised Myasthenia Gravis: A Tale of Two Targets
Managing Generalised Myasthenia Gravis: A Tale of Two Targets